Status:
NOT_YET_RECRUITING
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Lead Sponsor:
Mayo Clinic
Conditions:
Childhood Acute Lymphoblastic Leukemia
Childhood Lymphoblastic Lymphoma
Eligibility:
All Genders
Up to 21 years
Brief Summary
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA lev...
Eligibility Criteria
Inclusion
- Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team
- Receiving calaspargase as part of treatment for malignancy
Exclusion
- Age \> 21 years
- Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm
- Pregnancy
Key Trial Info
Start Date :
February 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07221656
Start Date
February 1 2026
End Date
December 31 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905